

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT5066830

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
WOJCIECH CZARDYBON	06/12/2015
KRZYSZTOF BRZÓZKA	06/12/2015
MICHAL GALEZOWSKI	06/12/2015
RENATA WINDAK	06/12/2015
MARIUSZ MILIK	06/12/2015
MAGDALENA ZAWADZKA	06/12/2015
PAWEL GUZIK	06/12/2015
EWELINA WINCZA	06/12/2015
MARTA PROKOP	06/14/2015
KATARZYNA WIKLIK	06/12/2015
ALEKSANDRA SABINIARZ	06/12/2015
WIESLAW MAREK CHOLODY	06/12/2015
RAYMOND HORVATH	05/26/2015
TOMASZ RZYMSKI	06/12/2015
RECEIVING PARTY DATA	
Name:	SELVITA S.A.
Street Address:	UL. BOBRZYNSKIEGO 14
City:	KRAKÓW
State/Country:	POLAND
Postal Code:	30-348
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	15179601
CORRESPONDENCE DATA	
Fax Number:	(202)371-2540
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	(202) 371-2600
Email:	jcovert@sternekessler.com, tarjahn@sternekessler.com, dcolonna@sternekessler.com
PATENT	

Correspondent Name: STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C
Address Line 1: 1100 NEW YORK AVENUE, N.W.
Address Line 4: WASHINGTON, D.C. 20005

ATTORNEY DOCKET NUMBER: 3240.0030002/JMC/THN

NAME OF SUBMITTER: JOHN M. COVERT, #38,759

SIGNATURE: /John M. Covert, #38,759/

DATE SIGNED: 07/25/2018

Total Attachments: 15

source=3240_0030002_Assignment#page1.tif
source=3240_0030002_Assignment#page2.tif
source=3240_0030002_Assignment#page3.tif
source=3240_0030002_Assignment#page4.tif
source=3240_0030002_Assignment#page5.tif
source=3240_0030002_Assignment#page6.tif
source=3240_0030002_Assignment#page7.tif
source=3240_0030002_Assignment#page8.tif
source=3240_0030002_Assignment#page9.tif
source=3240_0030002_Assignment#page10.tif
source=3240_0030002_Assignment#page11.tif
source=3240_0030002_Assignment#page12.tif
source=3240_0030002_Assignment#page13.tif
source=3240_0030002_Assignment#page14.tif
source=3240_0030002_Assignment#page15.tif

ASSIGNMENT

In consideration of the sum of One Dollar (\$1.00) or equivalent and other good and valuable consideration paid to each of the undersigned: Wojciech CZARDYBON, Krzysztof BRZÓZKA, Michał GALEZOWSKI, Renata WINDAK, Mariusz MILIK, Magdalena ZAWADZKA, Paweł GUZIK, Ewelina WINCZA, Marta PROKOP, Katarzyna WIKLIK, Aleksandra SABINIARZ, Wiesław Marek CHOŁODY, Raymond HORVATH and Tomasz RZYMSKI and hereby sell and assign to SELVITA S.A., a corporation formed under the laws of Poland, whose mailing address is ul. Bobrzynskiego 14, Kraków, 30-348 (PL) (hereafter referred to as the Assignee), his/her entire right, title and interest, including the right to sue for past infringement and to collect for all past, present and future damages, for the United States of America (as defined in 35 U.S.C. § 100) and throughout the world, in

(a) the invention(s) known as **Novel Benzimidazole Derivatives as Kinase Inhibitors** for which application(s) for patent in the United States of America has a filing date of _____ (also known as United States Application No. _____, which is the U.S. national phase of International Application No. PCT/EP2013/077754, International Filing Date December 20, 2013), in any and all applications thereon, in any and all Letters Patent(s) therefor, and

(b) any and all applications that claim the benefit of the patent application referenced in part (a), including non-provisional applications, continuing (continuation, divisional, or continuation-in-part) applications, reissues, extensions, renewals and reexaminations of the patent application, PCT applications, or national stage applications, or Letters Patent(s) that claim the benefit of the patent application referenced above in part (a), to the full extent of the term or terms for which Letters Patents issue, and

(c) any and all inventions described in the patent application referenced above in part (a), and in any and all forms of intellectual and industrial property protection derivable from such patent application, and that are derivable from any and all continuing applications, reissues, extensions, renewals and reexaminations of such patent application, including, without limitation, patents, applications, utility models, inventor's certificates, and designs together with the right to file applications therefor; and including the right to claim the same priority rights from any previously filed applications under the International Agreement for the Protection of Industrial Property, or any other international agreement, or the domestic laws of the country in which any such application is filed, as may be applicable;

all such rights, title and interest to be held and enjoyed by the above-named Assignee, its successors, legal representatives and assigns to the same extent as all such rights, title and interest would have been held and enjoyed by the Assignor had this assignment and sale not been made.

The undersigned inventors agree to execute all papers necessary in connection with the application(s) and any non-provisional, continuing (continuation, divisional, or continuation-in-part), reissue, reexamination or corresponding application(s) thereof and also to execute separate assignments in connection with such application(s) as the Assignee may deem necessary or expedient.






The undersigned inventors agree to execute all papers necessary in connection with any interference or patent enforcement action (judicial or otherwise) related to the application(s) or any non-provisional, continuing (continuation, divisional, or continuation-in-part), reissue or reexamination application(s) thereof and to cooperate with the Assignee in every way possible in obtaining evidence and going forward with such interference or patent enforcement action.

Each undersigned inventor hereby represents that he/she has full right to convey the entire interest herein assigned, and that he/she has not executed, and will not execute, any agreement that conflicts with the obligations herein.

Each of the undersigned inventors hereby grants the patent practitioners associated with **CUSTOMER NUMBER 26111** the power to insert in this assignment any further identification that may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office for recordation of this document.

Each undersigned inventor hereby represents that he/she understands that the patent practitioners associated with **CUSTOMER NUMBER 26111** are the legal representatives of, and attorneys for, the assignee, and are NOT the legal representatives of, or attorneys for, the inventors.

IN WITNESS WHEREOF, executed by the undersigned inventors on the date opposite his/her name.

Date: <u>12.06.2015</u>	Signature of Inventor: <u></u> Wojciech CZARDYBON
Date: <u>12.06.2015</u>	Signature of Inventor: <u></u> Krzysztof BRZÓZKA
Date: <u>12.06.2015</u>	Signature of Inventor: <u></u> Michał GALEZOWSKI
Date: <u>12.06.2015</u>	Signature of Inventor: <u></u> Renata WINDAK
Date: <u>12.06.2015</u>	Signature of Inventor: <u></u> Mariusz MILIK

Date: 12.06.2015

Signature of Inventor: Magdalena Zawadzka
Magdalena ZAWADZKA

Date: 12.06.2015

Signature of Inventor: Paweł Guzik
Paweł GUZIK

Date: 12.06.2015

Signature of Inventor: _____
Ewelina WINCZA

Date: 12.06.2015

Signature of Inventor: _____
Marta PROKOP

Date: 12.06.2015

Signature of Inventor: Katarzyna Wiklik
Katarzyna WIKLIK

Date: 12.06.2015

Signature of Inventor: Aleksandra Sabiniarz
Aleksandra SABINIARZ

Date: 12.06.2015

Signature of Inventor: _____
Wiesław Marek CHOŁODY

Date: 26.05.2015

Signature of Inventor: _____
Raymond HORVATH

Date: 12.06.2015

Signature of Inventor: Tomasz Rzymski
Tomasz RZYMSKI

1995839_1.DOCX

ASSIGNMENT

In consideration of the sum of One Dollar (\$1.00) or equivalent and other good and valuable consideration paid to each of the undersigned: Wojciech CZARDYBON, Krzysztof BRZÓZKA, Michał GALEZOWSKI, Renata WINDAK, Mariusz MILIK, Magdalena ZAWADZKA, Paweł GUZIK, Ewelina WINCZA, Marta PROKOP, Katarzyna WIKLIK, Aleksandra SABINIARZ, Wiesław Marek CHOŁODY, Raymond HORVATH and Tomasz RZYMSKI and hereby sell and assign to SELVITA S.A., a corporation formed under the laws of Poland, whose mailing address is ul. Bobrzynskiego 14, Kraków, 30-348 (PL) (hereafter referred to as the Assignee), his/her entire right, title and interest, including the right to sue for past infringement and to collect for all past, present and future damages, for the United States of America (as defined in 35 U.S.C. § 100) and throughout the world, in

(a) the invention(s) known as **Novel Benzimidazole Derivatives as Kinase Inhibitors** for which application(s) for patent in the United States of America has a filing date of _____ (also known as United States Application No. _____, which is the U.S. national phase of International Application No. PCT/EP2013/077754, International Filing Date December 20, 2013), in any and all applications thereon, in any and all Letters Patent(s) therefor, and

(b) any and all applications that claim the benefit of the patent application referenced in part (a), including non-provisional applications, continuing (continuation, divisional, or continuation-in-part) applications, reissues, extensions, renewals and reexaminations of the patent application, PCT applications, or national stage applications, or Letters Patent(s) that claim the benefit of the patent application referenced above in part (a), to the full extent of the term or terms for which Letters Patents issue, and

(c) any and all inventions described in the patent application referenced above in part (a), and in any and all forms of intellectual and industrial property protection derivable from such patent application, and that are derivable from any and all continuing applications, reissues, extensions, renewals and reexaminations of such patent application, including, without limitation, patents, applications, utility models, inventor's certificates, and designs together with the right to file applications therefor; and including the right to claim the same priority rights from any previously filed applications under the International Agreement for the Protection of Industrial Property, or any other international agreement, or the domestic laws of the country in which any such application is filed, as may be applicable;

all such rights, title and interest to be held and enjoyed by the above-named Assignee, its successors, legal representatives and assigns to the same extent as all such rights, title and interest would have been held and enjoyed by the Assignor had this assignment and sale not been made.

The undersigned inventors agree to execute all papers necessary in connection with the application(s) and any non-provisional, continuing (continuation, divisional, or continuation-in-part), reissue, reexamination or corresponding application(s) thereof and also to execute separate assignments in connection with such application(s) as the Assignee may deem necessary or expedient.

The undersigned inventors agree to execute all papers necessary in connection with any interference or patent enforcement action (judicial or otherwise) related to the application(s) or any non-provisional, continuing (continuation, divisional, or continuation-in-part), reissue or reexamination application(s) thereof and to cooperate with the Assignee in every way possible in obtaining evidence and going forward with such interference or patent enforcement action.

Each undersigned inventor hereby represents that he/she has full right to convey the entire interest herein assigned, and that he/she has not executed, and will not execute, any agreement that conflicts with the obligations herein.

Each of the undersigned inventors hereby grants the patent practitioners associated with **CUSTOMER NUMBER 26111** the power to insert in this assignment any further identification that may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office for recordation of this document.

Each undersigned inventor hereby represents that he/she understands that the patent practitioners associated with **CUSTOMER NUMBER 26111** are the legal representatives of, and attorneys for, the assignee, and are NOT the legal representatives of, or attorneys for, the inventors.

IN WITNESS WHEREOF, executed by the undersigned inventors on the date opposite his/her name.

Date: _____ Signature of Inventor: _____
Wojciech CZARDYBON

Date: _____ Signature of Inventor: _____
Krzysztof BRZÓZKA

Date: _____ Signature of Inventor: _____
Michał GALEZOWSKI

Date: _____ Signature of Inventor: _____
Renata WINDAK

Date: _____ Signature of Inventor: _____
Mariusz MILIK

Date: _____ Signature of Inventor: _____
Magdalena ZAWADZKA

Date: _____ Signature of Inventor: _____
Pawel GUZIK

Date: 12.06.2015 Signature of Inventor: Ewelina Wincza
Ewelina WINCZA

Date: _____ Signature of Inventor: _____
Marta PROKOP

Date: _____ Signature of Inventor: _____
Katarzyna WIKLIK

Date: _____ Signature of Inventor: _____
Aleksandra SABINIARZ

Date: _____ Signature of Inventor: _____
Wieslaw Marek CHOŁODY

Date: _____ Signature of Inventor: _____
Raymond HORVATH

Date: _____ Signature of Inventor: _____
Tomasz RZYMSKI

1995839_1.DOCX

ASSIGNMENT

In consideration of the sum of One Dollar (\$1.00) or equivalent and other good and valuable consideration paid to each of the undersigned: Wojciech CZARDYBON, Krzysztof BRZÓZKA, Michał GALEZOWSKI, Renata WINDAK, Mariusz MILIK, Magdalena ZAWADZKA, Paweł GUZIK, Ewelina WINCZA, Marta PROKOP, Katarzyna WIKLIK, Aleksandra SABINIARZ, Wiesław Marek CHOŁODY, Raymond HORVATH and Tomasz RZYMSKI and hereby sell and assign to SELVITA S.A., a corporation formed under the laws of Poland, whose mailing address is ul. Bobrzynskiego 14, Kraków, 30-348 (PL) (hereafter referred to as the Assignee), his/her entire right, title and interest, including the right to sue for past infringement and to collect for all past, present and future damages, for the United States of America (as defined in 35 U.S.C. § 100) and throughout the world, in

(a) the invention(s) known as **Novel Benzimidazole Derivatives as Kinase Inhibitors** for which application(s) for patent in the United States of America has a filing date of _____ (also known as United States Application No. _____, which is the U.S. national phase of International Application No. PCT/EP2013/077754, International Filing Date December 20, 2013), in any and all applications thereon, in any and all Letters Patent(s) therefor, and

(b) any and all applications that claim the benefit of the patent application referenced in part (a), including non-provisional applications, continuing (continuation, divisional, or continuation-in-part) applications, reissues, extensions, renewals and reexaminations of the patent application, PCT applications, or national stage applications, or Letters Patent(s) that claim the benefit of the patent application referenced above in part (a), to the full extent of the term or terms for which Letters Patents issue, and

(c) any and all inventions described in the patent application referenced above in part (a), and in any and all forms of intellectual and industrial property protection derivable from such patent application, and that are derivable from any and all continuing applications, reissues, extensions, renewals and reexaminations of such patent application, including, without limitation, patents, applications, utility models, inventor's certificates, and designs together with the right to file applications therefor; and including the right to claim the same priority rights from any previously filed applications under the International Agreement for the Protection of Industrial Property, or any other international agreement, or the domestic laws of the country in which any such application is filed, as may be applicable;

all such rights, title and interest to be held and enjoyed by the above-named Assignee, its successors, legal representatives and assigns to the same extent as all such rights, title and interest would have been held and enjoyed by the Assignor had this assignment and sale not been made.

The undersigned inventors agree to execute all papers necessary in connection with the application(s) and any non-provisional, continuing (continuation, divisional, or continuation-in-part), reissue, reexamination or corresponding application(s) thereof and also to execute separate assignments in connection with such application(s) as the Assignee may deem necessary or expedient.

The undersigned inventors agree to execute all papers necessary in connection with any interference or patent enforcement action (judicial or otherwise) related to the application(s) or any non-provisional, continuing (continuation, divisional, or continuation-in-part), reissue or reexamination application(s) thereof and to cooperate with the Assignee in every way possible in obtaining evidence and going forward with such interference or patent enforcement action.

Each undersigned inventor hereby represents that he/she has full right to convey the entire interest herein assigned, and that he/she has not executed, and will not execute, any agreement that conflicts with the obligations herein.

Each of the undersigned inventors hereby grants the patent practitioners associated with **CUSTOMER NUMBER 26111** the power to insert in this assignment any further identification that may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office for recordation of this document.

Each undersigned inventor hereby represents that he/she understands that the patent practitioners associated with **CUSTOMER NUMBER 26111** are the legal representatives of, and attorneys for, the assignee, and are NOT the legal representatives of, or attorneys for, the inventors.

IN WITNESS WHEREOF, executed by the undersigned inventors on the date opposite his/her name.

Date: _____ Signature of Inventor: _____
Wojciech CZARDYBON

Date: _____ Signature of Inventor: _____
Krzysztof BRZÓZKA

Date: _____ Signature of Inventor: _____
Michal GALEZOWSKI

Date: _____ Signature of Inventor: _____
Renata WINDAK

Date: _____ Signature of Inventor: _____
Mariusz MILIK

Date: _____ Signature of Inventor: _____
Magdalena ZAWADZKA

Date: _____ Signature of Inventor: _____
Pawel GUZIK

Date: _____ Signature of Inventor: _____
Ewelina WINCZA

Date: 14.06.2015 Signature of Inventor: Marta Prokop
Marta PROKOP

Date: _____ Signature of Inventor: _____
Katarzyna WIKLIK

Date: _____ Signature of Inventor: _____
Aleksandra SABINIARZ

Date: _____ Signature of Inventor: _____
Wieslaw Marek CHOŁODY

Date: _____ Signature of Inventor: _____
Raymond HORVATH

Date: _____ Signature of Inventor: _____
Tomasz RZYMSKI

1995839_1.DOCX

ASSIGNMENT

In consideration of the sum of One Dollar (\$1.00) or equivalent and other good and valuable consideration paid to each of the undersigned: Wojciech CZARDYBON, Krzysztof BRZÓZKA, Michał GALEZOWSKI, Renata WINDAK, Mariusz MILIK, Magdalena ZAWADZKA, Paweł GUZIK, Ewelina WINCZA, Marta PROKOP, Katarzyna WIKLIK, Aleksandra SABINIARZ, Wiesław Marek CHOŁODY, Raymond HORVATH and Tomasz RZYMSKI and hereby sell and assign to SELVITA S.A., a corporation formed under the laws of Poland, whose mailing address is ul. Bobrzynskiego 14, Kraków, 30-348 (PL) (hereafter referred to as the Assignee), his/her entire right, title and interest, including the right to sue for past infringement and to collect for all past, present and future damages, for the United States of America (as defined in 35 U.S.C. § 100) and throughout the world, in

(a) the invention(s) known as **Novel Benzimidazole Derivatives as Kinase Inhibitors** for which application(s) for patent in the United States of America has a filing date of _____ (also known as United States Application No. _____, which is the U.S. national phase of International Application No. PCT/EP2013/077754, International Filing Date December 20, 2013), in any and all applications thereon, in any and all Letters Patent(s) therefor, and

(b) any and all applications that claim the benefit of the patent application referenced in part (a), including non-provisional applications, continuing (continuation, divisional, or continuation-in-part) applications, reissues, extensions, renewals and reexaminations of the patent application, PCT applications, or national stage applications, or Letters Patent(s) that claim the benefit of the patent application referenced above in part (a), to the full extent of the term or terms for which Letters Patents issue, and

(c) any and all inventions described in the patent application referenced above in part (a), and in any and all forms of intellectual and industrial property protection derivable from such patent application, and that are derivable from any and all continuing applications, reissues, extensions, renewals and reexaminations of such patent application, including, without limitation, patents, applications, utility models, inventor's certificates, and designs together with the right to file applications therefor; and including the right to claim the same priority rights from any previously filed applications under the International Agreement for the Protection of Industrial Property, or any other international agreement, or the domestic laws of the country in which any such application is filed, as may be applicable;

all such rights, title and interest to be held and enjoyed by the above-named Assignee, its successors, legal representatives and assigns to the same extent as all such rights, title and interest would have been held and enjoyed by the Assignor had this assignment and sale not been made.

The undersigned inventors agree to execute all papers necessary in connection with the application(s) and any non-provisional, continuing (continuation, divisional, or continuation-in-part), reissue, reexamination or corresponding application(s) thereof and also to execute separate assignments in connection with such application(s) as the Assignee may deem necessary or expedient.

The undersigned inventors agree to execute all papers necessary in connection with any interference or patent enforcement action (judicial or otherwise) related to the application(s) or any non-provisional, continuing (continuation, divisional, or continuation-in-part), reissue or reexamination application(s) thereof and to cooperate with the Assignee in every way possible in obtaining evidence and going forward with such interference or patent enforcement action.

Each undersigned inventor hereby represents that he/she has full right to convey the entire interest herein assigned, and that he/she has not executed, and will not execute, any agreement that conflicts with the obligations herein.

Each of the undersigned inventors hereby grants the patent practitioners associated with **CUSTOMER NUMBER 26111** the power to insert in this assignment any further identification that may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office for recordation of this document.

Each undersigned inventor hereby represents that he/she understands that the patent practitioners associated with **CUSTOMER NUMBER 26111** are the legal representatives of, and attorneys for, the assignee, and are NOT the legal representatives of, or attorneys for, the inventors.

IN WITNESS WHEREOF, executed by the undersigned inventors on the date opposite his/her name.

Date: _____ Signature of Inventor: _____
Wojciech CZARDYBON

Date: _____ Signature of Inventor: _____
Krzysztof BRZÓZKA

Date: _____ Signature of Inventor: _____
Michał GALEZOWSKI

Date: _____ Signature of Inventor: _____
Renata WINDAK

Date: _____ Signature of Inventor: _____
Mariusz MILIK

Date: _____ Signature of Inventor: _____
Magdalena ZAWADZKA


Date: _____ Signature of Inventor: _____
Pawel GUZIK

Date: _____ Signature of Inventor: _____
Ewelina WINCZA

Date: _____ Signature of Inventor: _____
Marta PROKOP

Date: _____ Signature of Inventor: _____
Katarzyna WIKLIK

Date: _____ Signature of Inventor: _____
Aleksandra SABINIARZ

Date: _____ Signature of Inventor:  _____
Wieslaw Marek CHOŁODY

Date: _____ Signature of Inventor: _____
Raymond HORVATH

Date: _____ Signature of Inventor: _____
Tomasz RZYMSKI

1995839_1.DOCX

ASSIGNMENT

In consideration of the sum of One Dollar (\$1.00) or equivalent and other good and valuable consideration paid to each of the undersigned: Wojciech CZARDYBON, Krzysztof BRZÓZKA, Michał GALEZOWSKI, Renata WINDAK, Mariusz MILIK, Magdalena ZAWADZKA, Paweł GUZIK, Ewelina WINCZA, Marta PROKOP, Katarzyna WIKLIK, Aleksandra SABINIARZ, Wiesław Marek CHOŁODY, Raymond HORVATH and Tomasz RZYMSKI and hereby sell and assign to SELVITA S.A., a corporation formed under the laws of Poland, whose mailing address is ul. Bobrzynskiego 14, Kraków, 30-348 (PL) (hereafter referred to as the Assignee), his/her entire right, title and interest, including the right to sue for past infringement and to collect for all past, present and future damages, for the United States of America (as defined in 35 U.S.C. § 100) and throughout the world, in

(a) the invention(s) known as **Novel Benzimidazole Derivatives as Kinase Inhibitors** for which application(s) for patent in the United States of America has a filing date of _____ (also known as United States Application No. _____, which is the U.S. national phase of International Application No. PCT/EP2013/077754, International Filing Date December 20, 2013), in any and all applications thereon, in any and all Letters Patent(s) therefor, and

(b) any and all applications that claim the benefit of the patent application referenced in part (a), including non-provisional applications, continuing (continuation, divisional, or continuation-in-part) applications, reissues, extensions, renewals and reexaminations of the patent application, PCT applications, or national stage applications, or Letters Patent(s) that claim the benefit of the patent application referenced above in part (a), to the full extent of the term or terms for which Letters Patents issue, and

(c) any and all inventions described in the patent application referenced above in part (a), and in any and all forms of intellectual and industrial property protection derivable from such patent application, and that are derivable from any and all continuing applications, reissues, extensions, renewals and reexaminations of such patent application, including, without limitation, patents, applications, utility models, inventor's certificates, and designs together with the right to file applications therefor; and including the right to claim the same priority rights from any previously filed applications under the International Agreement for the Protection of Industrial Property, or any other international agreement, or the domestic laws of the country in which any such application is filed, as may be applicable;

all such rights, title and interest to be held and enjoyed by the above-named Assignee, its successors, legal representatives and assigns to the same extent as all such rights, title and interest would have been held and enjoyed by the Assignor had this assignment and sale not been made.

The undersigned inventors agree to execute all papers necessary in connection with the application(s) and any non-provisional, continuing (continuation, divisional, or continuation-in-part), reissue, reexamination or corresponding application(s) thereof and also to execute separate assignments in connection with such application(s) as the Assignee may deem necessary or expedient.

The undersigned inventors agree to execute all papers necessary in connection with any interference or patent enforcement action (judicial or otherwise) related to the application(s) or any non-provisional, continuing (continuation, divisional, or continuation-in-part), reissue or reexamination application(s) thereof and to cooperate with the Assignee in every way possible in obtaining evidence and going forward with such interference or patent enforcement action.

Each undersigned inventor hereby represents that he/she has full right to convey the entire interest herein assigned, and that he/she has not executed, and will not execute, any agreement that conflicts with the obligations herein.

Each of the undersigned inventors hereby grants the patent practitioners associated with **CUSTOMER NUMBER 26111** the power to insert in this assignment any further identification that may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office for recordation of this document.

Each undersigned inventor hereby represents that he/she understands that the patent practitioners associated with **CUSTOMER NUMBER 26111** are the legal representatives of, and attorneys for, the assignee, and are NOT the legal representatives of, or attorneys for, the inventors.

IN WITNESS WHEREOF, executed by the undersigned inventors on the date opposite his/her name.


Date: _____ Signature of Inventor: _____
Wojciech CZARDYBON

Date: _____ Signature of Inventor: _____
Krzysztof BRZÓZKA

Date: _____ Signature of Inventor: _____
Michal GALEZOWSKI

Date: _____ Signature of Inventor: _____
Renata WINDAK

Date: _____ Signature of Inventor: _____
Mariusz MILIK

Date: _____	Signature of Inventor: _____ Magdalena ZAWADZKA
Date: _____	Signature of Inventor: _____ Pawel GUZIK
Date: _____	Signature of Inventor: _____ Ewelina WINCZA
Date: _____	Signature of Inventor: _____ Marta PROKOP
Date: _____	Signature of Inventor: _____ Katarzyna WIKLIK
Date: _____	Signature of Inventor: _____ Aleksandra SABINIARZ
Date: _____	Signature of Inventor: _____ Wieslaw Marek CHOLODY
Date: <u>May 26, 2015</u>	Signature of Inventor:  Raymond HORVATH
Date: _____	Signature of Inventor: _____ Tomasz RZYMSKI

1995839_1.DOCX